Tandem Diabetes Net Worth
Tandem Diabetes Net Worth Breakdown | TNDM |
Tandem Diabetes Net Worth Analysis
Tandem Diabetes' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Tandem Diabetes' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Tandem Diabetes' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Tandem Diabetes' net worth analysis. One common approach is to calculate Tandem Diabetes' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Tandem Diabetes' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Tandem Diabetes' net worth. This approach calculates the present value of Tandem Diabetes' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Tandem Diabetes' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Tandem Diabetes' net worth. This involves comparing Tandem Diabetes' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Tandem Diabetes' net worth relative to its peers.
Enterprise Value |
|
To determine if Tandem Diabetes is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Tandem Diabetes' net worth research are outlined below:
| Tandem Diabetes Care generated a negative expected return over the last 90 days | |
| Tandem Diabetes Care has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M. | |
| Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47. | |
| Tandem Diabetes Care has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Blickenstaff Kim D of Tandem Diabetes at 30.0 subject to Rule 16b-3 |
Tandem Diabetes uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Tandem Diabetes Care. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Tandem Diabetes' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Tandem Diabetes' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tandem Diabetes is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tandem Diabetes Care backward and forwards among themselves. Tandem Diabetes' institutional investor refers to the entity that pools money to purchase Tandem Diabetes' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ameriprise Financial Inc | 2024-06-30 | 1.5 M | Champlain Investment Partners, Llc | 2024-09-30 | 1.5 M | Hhg Plc | 2024-06-30 | 1.5 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 1.3 M | Two Sigma Advisers, Llc | 2024-06-30 | 1.1 M | Park West Asset Management Llc | 2024-09-30 | 1.1 M | Millennium Management Llc | 2024-06-30 | 1.1 M | Divisadero Street Capital Management, Lp | 2024-09-30 | 1.1 M | First Light Asset Management, Llc | 2024-09-30 | 1 M | Blackrock Inc | 2024-06-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 7.4 M |
Follow Tandem Diabetes' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.02 B.Market Cap |
|
Project Tandem Diabetes' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.23) | (0.25) | |
| Return On Capital Employed | (0.31) | (0.29) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (0.71) | (0.67) |
When accessing Tandem Diabetes' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Tandem Diabetes' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Tandem Diabetes' profitability and make more informed investment decisions.
Evaluate Tandem Diabetes' management efficiency
Tandem Diabetes Care has return on total asset (ROA) of (0.0969) % which means that it has lost $0.0969 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4596) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.29. At this time, Tandem Diabetes' Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Debt To Assets is likely to grow to 0.41, while Return On Tangible Assets are likely to drop (0.25).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.83 | 4.59 | |
| Tangible Book Value Per Share | 4.79 | 4.55 | |
| Enterprise Value Over EBITDA | (11.70) | (12.28) | |
| Price Book Value Ratio | 6.12 | 4.71 | |
| Enterprise Value Multiple | (11.70) | (12.28) | |
| Price Fair Value | 6.12 | 4.71 | |
| Enterprise Value | 2 B | 2.2 B |
Management at Tandem Diabetes Care focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 2.3715 | Revenue 854.4 M | Quarterly Revenue Growth 0.314 | Revenue Per Share 13.082 | Return On Equity (0.46) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tandem Diabetes insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tandem Diabetes' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tandem Diabetes insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tandem Diabetes Corporate Filings
F4 | 22nd of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 26th of June 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Tandem Diabetes Earnings per Share Projection vs Actual
Tandem Diabetes Corporate Management
| Tom Fox | Chief Officer | Profile | |
| Susan Morrison | Chief Admin. Officer | Profile | |
| Mark Novara | Executive Officer | Profile | |
| Ross Sylvia | VP Marketing | Profile | |
| David Esq | Transitional Advisor | Profile | |
| Jordan MD | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share 13.082 | Quarterly Revenue Growth 0.314 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.